IsoPlexis (IsoPlexis) Debt-to-Equity : 1.25 (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis Debt-to-Equity?

IsoPlexis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $1.59 Mil. IsoPlexis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $50.09 Mil. IsoPlexis's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $41.27 Mil. IsoPlexis's debt to equity for the quarter that ended in Dec. 2022 was 1.25.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for IsoPlexis's Debt-to-Equity or its related term are showing as below:

ISO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.22 Med: 0.24 Max: 1.25
Current: 1.25

During the past 4 years, the highest Debt-to-Equity Ratio of IsoPlexis was 1.25. The lowest was 0.22. And the median was 0.24.

ISO's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.21 vs ISO: 1.25

IsoPlexis Debt-to-Equity Historical Data

The historical data trend for IsoPlexis's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis Debt-to-Equity Chart

IsoPlexis Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

0.24

0.22

1.25

IsoPlexis Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-Equity	Get a 7-Day Free Trial								0.22	0.39	0.57	0.70	1.25

Competitive Comparison of IsoPlexis's Debt-to-Equity

For the Medical Devices subindustry, IsoPlexis's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IsoPlexis's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where IsoPlexis's Debt-to-Equity falls into.

IsoPlexis Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

IsoPlexis's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.588	+	50.09)	/	41.267
	=	1.25

IsoPlexis's Debt to Equity Ratio for the quarter that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.588	+	50.09)	/	41.267
	=	1.25

IsoPlexis (NAS:ISO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

IsoPlexis Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of IsoPlexis's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IsoPlexis (IsoPlexis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 North East Industrial Road, Branford, CT, USA, 06405

Website

https://www.isoplexis.com

IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.

Executives

Nachum Shamir	director	12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley	officer: Chief Financial Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay	director, officer: Chief Executive Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii	officer: SVP, GC & Secretary	7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath	director	C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm	director	1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia	director	7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers	director	C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley	director	396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho	director, 10 percent owner	C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel	officer: Chief Commercial Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou	officer: Chief Scientific Officer	35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar	officer: VP, Finance	35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc	10 percent owner	4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003